PDCD1 and neoplasm: In fact, while addition of a SHP2 inhibitor along with RASG12C(ON) inhibition provides a survival benefit, it is the combination of RASG12C(ON) inhibition with anti-PD-1 blockade that is the major driver for tumour eradication in preclinical models with a degree of intrinsic sensitivity to ICB, confirming the critical role of adaptive immunity in the generation of durable responses.